Cleave Biosciences Names Tim Smith as Chief Business Officer

BURLINGAME, Calif., June 1, 2016 /PRNewswire/ -- Cleave Biosciences today announced Tim Smith has joined the company as chief business officer. In this newly created executive position, Mr. Smith is responsible for business development, corporate development and investor relations as Cleave advances its novel protein homeostasis inhibitors currently under development for the treatment of cancer.

"Tim's deep business and biotechnology expertise, which includes leading significant licensing and M&A transactions, will be invaluable as we pursue our business and product development plans," said Laura Shawver, Ph.D., chief executive officer of Cleave Biosciences. "We look forward to leveraging his experience to identify and foster new strategic opportunities as we continue the clinical trials of CB-5083, our lead drug candidate, and develop additional first-in-class agents targeting the AAA ATPase family."

"Cleave Biosciences has all of the attributes of a successful drug discovery company: an experienced management team, exceptional venture and corporate investors, and highly differentiated drug candidates," said Mr. Smith. "I am eager to join the company as we initiate additional clinical trials for CB-5083 and translate our novel science into a powerful strategy for treating patients with difficult to treat solid tumor and hematologic malignancies." 

Mr. Smith has more than 15 years of experience in the life sciences industry. Prior to joining Cleave, he was executive director, business development at Celgene Corporation. In this role, he led numerous M&A, in-licensing and strategic equity investment transactions. Mr. Smith joined Celgene in 2009 as director, investor relations and subsequently led the business planning and analysis function. Prior to joining Celgene, he was director, investor relations at MGI PHARMA, Inc. He spent the majority of his early career in equity research covering the biotechnology sector at RBC Capital Markets, Lazard Capital Markets and Citi Research. He began his career as a research technician at the Skirball Institute of Biomolecular Medicine. Mr. Smith holds a B.S. in biology from the University of Texas at Arlington, an M.B.A. in finance from Fordham University and an M.A. in biotechnology from Columbia University.

About Cleave Biosciences

Biopharmaceutical company Cleave Biosciences is a pioneer in the discovery and development of drugs that target protein homeostasis systems and have the potential to transform the treatment of people with difficult to treat solid tumors and hematologic malignancies. The company is privately held and located in Burlingame, California. For additional information, visit www.cleavebio.com.

SOURCE Cleave Biosciences

Related Links

http://www.cleavebio.com